journeypax.blogg.se

Rapt therapeutics stock
Rapt therapeutics stock










rapt therapeutics stock rapt therapeutics stock

Cantor Fitzgerald decreased their target price on RAPT Therapeutics from $71.00 to $58.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 16th. They set an “overweight” rating and a $61.00 target price on the stock. started coverage on RAPT Therapeutics in a research report on Thursday, December 9th. will post -2.67 EPS for the current year.Ī number of research analysts have recently issued reports on RAPT shares. On average, equities analysts expect that RAPT Therapeutics, Inc. The company had revenue of $0.97 million during the quarter, compared to analyst estimates of $1.45 million. RAPT Therapeutics had a negative return on equity of 41.61% and a negative net margin of 1,468.46%. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). RAPT Therapeutics (NASDAQ:RAPT) last issued its earnings results on Wednesday, November 10th. The stock has a fifty day simple moving average of $34.14 and a two-hundred day simple moving average of $33.39. The company has a market capitalization of $874.56 million, a PE ratio of -12.13 and a beta of 0.15.

rapt therapeutics stock

Shares of RAPT opened at $29.60 on Friday. The shares were sold at an average price of $32.26, for a total value of $96,780.00. On Friday, December 3rd, William Ho sold 3,000 shares of RAPT Therapeutics stock.

rapt therapeutics stock

The shares were sold at an average price of $40.00, for a total value of $80,000.00.

  • On Wednesday, January 5th, William Ho sold 2,000 shares of RAPT Therapeutics stock.
  • William Ho also recently made the following trade(s): The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The stock was sold at an average price of $30.67, for a total value of $92,010.00. (NASDAQ:RAPT) insider William Ho sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, January 13th. All Rights Reserved.RAPT Therapeutics, Inc. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. Factset: FactSet Research Systems Inc.2019. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes.












    Rapt therapeutics stock